Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2004

View Archived Issues

Naturally occurring spirostenol prevents beta-amyloid-induced toxicity

Identification of active metabolites of selective COX-2 inhibitor

Behavioral improvements associated with sertraline in Alzheimer's disease

Improved glycemic control achieved with repaglinide plus pioglitazone in type 2 diabetes

Clavulanate improves the efficacy of standard therapy for H. pylori infection

Although ineffective alone, NAC in combination with deferoxamine is protective in a rat sepsis model

AnGes files IND for phase I trials of HGF

Technology transfer completed in Actelion/Merck renin alliance

Ultrafine completes scale-up of PPA-605 and PPA-904

Abbott and Corixa in agreement for Chagas' disease blood screening technology

Preliminary findings from Women's Health Initiative and memory substudy

Yakult Honsha files Japanese import application for oxaliplatin

Transgene highlights 2003 developments

Avigen continues to move forward with product development portfolio

Lilly claims new SERMs for endometriosis and uterine leiomyoma therapy

Novel NO-releasing prodrugs of COX-2 inhibitors and their use

Two novel series of chemokine CCR1 antagonists identified at Pfizer

NeuroSearch team prepares and tests new opioid receptor ligands

Guanylate cyclase as a target for the treatment of cognitive disorders

Novel iNOS inhibitors for IBD, arthritis and pain designed at AstraZeneca

Micrologix presents nucleoside-based anti-HBV agents

NIH licensing technology for improved process to produce the steroid CDB-2914

SR-4554 available for licensing from Cancer Research Technology

Canadian approval for one- and three-month Eligard products

New phase II trial for insulin sensitizer MBX-102

Phase I trials for DRF-10945 commence in Canada

German approval for Gamunex

Japanese approval for Serevent 50 Diskus

Aldara approved for actinic keratoses

Altastaph receives fast track designation

Hemispherx Biopharma cleared to commence phase II Alferon LDO study